10.25384/SAGE.12311060.v1 Helmut Butzkueven Helmut Butzkueven Maria Trojano Maria Trojano Ludwig Kappos Ludwig Kappos Tim Spelman Tim Spelman Heinz Wiendl Heinz Wiendl Karen Rosales Karen Rosales Ray Su Ray Su Stephanie Licata Stephanie Licata Pei-Ran Ho Pei-Ran Ho Nolan Campbell Nolan Campbell MSJ917925_supplemental_figure_1 – Supplemental material for Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri<sup>®</sup> Observational Program (TOP) SAGE Journals 2020 Discontinuation disease-modifying therapy multiple sclerosis natalizumab observational study relapse 2020-05-15 12:10:38 Journal contribution https://sage.figshare.com/articles/journal_contribution/MSJ917925_supplemental_figure_1_Supplemental_material_for_Clinical_outcomes_in_patients_who_discontinue_natalizumab_therapy_after_2_years_in_the_Tysabri_sup_sup_Observational_Program_TOP_/12311060 <p>Supplemental material, MSJ917925_supplemental_figure_1 for Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri<sup>®</sup> Observational Program (TOP) by Helmut Butzkueven, Maria Trojano, Ludwig Kappos, Tim Spelman, Heinz Wiendl, Karen Rosales, Ray Su, Stephanie Licata, Pei-Ran Ho and Nolan Campbell in Multiple Sclerosis Journal</p>